A Class I recall involving Medline’s Namic Angiographic Rotating Adaptor Control Syringes is drawing attention across the U.S. surgical and interventional supply market because it affects a product used in contrast-delivery workflows where connection integrity is critical. The U.S. Food and Drug Administration said the rotating adaptor on the affected syringe may unwind during use, creating either a loose connection or a full disconnection between the syringe and the manifold. In practical terms, that means a small component failure can quickly become a patient safety issue during angiographic and other contrast-based procedures. For hospitals, ambulatory procedural centers, cath labs, and distributors, the recall is not only a safety notice but also a supply chain event that requires immediate inventory review and workflow adjustments.
The FDA classified the Medline action as a Class I recall, the agency’s most serious recall category. That classification is reserved for situations in which use of the product could cause serious injury or death. According to the FDA, the issue involves certain Namic Angiographic RA Control Syringes as well as convenience kits that contain those syringes. The recall centers on the risk that the rotating adaptor may unwind, compromising the connection point during the administration of radiographic contrast media.
The agency said that if the connection becomes loose or disconnects entirely, the consequences may include biohazard exposure, blood loss, infection, introduction of air into the line, and possible air embolism. In procedure rooms, these are not minor technical faults. They are events that can interrupt a case, force emergency troubleshooting, and potentially harm the patient. As of March 13, 2026, the FDA said there had been four serious injuries reported in connection with the problem and no deaths. Even without reported deaths, the seriousness of the potential failure mode explains why the recall was elevated to the highest classification.
This recall matters because angiographic syringes are embedded in routine procedural workflows, particularly in settings that handle cardiovascular, vascular, and interventional imaging cases. A defect in a disposable accessory can create disproportionate disruption because it touches both patient care and the broader supply process. When a Class I recall is issued, hospitals are not simply replacing one item number. They may need to identify all affected inventory, check unopened kits, revise preference cards, communicate with clinical leaders, and validate substitute products under time pressure.
There is also a purchasing dimension. A recall involving a connection-critical device tends to prompt buyers to ask broader questions about quality oversight, complaint handling, and backup sourcing. The FDA’s separate warning letter to Medline adds weight to that concern. In the letter, the agency described quality-system issues related to complaint investigations and the company’s handling of risks associated with the syringe-manifold disconnection issue. That means the market is not just looking at one defective product; many procurement teams will also be evaluating the reliability of manufacturing controls and whether similar vulnerabilities could affect adjacent product lines.
The immediate impact falls on hospital supply chain departments, cath labs, interventional radiology teams, clinicians using angiographic systems, sterile supply personnel, and distributors that stocked or redistributed the affected products. Organizations with Medline convenience kits in circulation may face additional work because the issue is not limited to standalone syringes. Affected kits may still need to be opened, identified, over-labeled, or otherwise modified so that the recalled syringe component is removed and discarded before patient use.
Becker’s Hospital Review reported that the recall also involved 966 convenience kits, broadening the operational reach of the event. That is important because kit-based distribution can spread risk into multiple departments that may not initially realize they are carrying a recalled component. In other words, a syringe defect may not stay isolated to a single specialty shelf. It can move through packaged supply systems into wider procedural use, which makes recall execution more complicated for health systems trying to ensure no affected units remain in circulation.
From a strategic market perspective, this recall highlights a recurring vulnerability in the surgical and interventional supply chain: small disposable components can carry outsized clinical and commercial risk. A facility may have high confidence in its larger capital platforms, but if a single-use connection device fails at a critical moment, the entire workflow is exposed. According to the FDA, the failure mode here can create conditions that lead to blood loss, infection risk, and air embolism. That makes the issue especially relevant to providers evaluating supply continuity and vendor risk management in high-acuity environments.
